Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439353 | 1.00 | NPC1 (0.55) | NPC1MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL1439357 | 1.00 | NPC1 (0.55) | NPC1MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL13868568 | 0.88 | NPC1 (0.54) | NPC1MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL13786813 | 0.88 | NPC1 (0.54) | NPC1MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL25012609 | 0.83 | NPC1 (0.46) | NPC1MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL1556751 | 0.83 | NPC1 (0.64) | NPC1MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL5995010 | 0.83 | NPC1 (0.46) | NPC1MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL1556749 | 0.83 | NPC1 (0.64) | NPC1MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL10358866 | 0.82 | NPC1 (0.55) | NPC1MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL27776082 | 0.82 | MAPT (0.55) | NPC1MAPTRAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737470-A2 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | Zikani Therapeutics , Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3883647-B1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIOVENTURES, INC., | 2025-07-10 | — | — | US | disclosed |
| CN-119522215-A | TEAD inhibitors and methods of use | 思博睿生物探索公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4496789-A1 | TEAD INHIBITORS AND METHODS OF USE | Sporos Biodiscovery, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023183437-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| CN-113573779-A | C10-alkylene substituted 13-membered macrolides and their use | 齐卡尼治疗股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| WO-2009079627-A2 | REAGENTS AND METHODS FOR THE BETA-KETO AMIDE SYNTHESIS OF A SYNTHETIC PRECURSOR TO IMMUNOLOGICAL ADJUVANT E6020 | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-06-25 | — | — | WO | disclosed |
| US-7550501-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550501-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| EP-1511499-B1 | IMMUNOMODULATORY COMPOUNDS AND METHODS OF USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070082875-A1 | toll-like receptor-4 agonists; vaccines | EISAI CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070082875-A1 | toll-like receptor-4 agonists; vaccines | EISAI CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-7202234-B2 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
| WO-2007005583-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI CO., LTD. (JP) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | MALT1, CCR10, CYP51A1 | NPC1 12/4885MAPT 4810/4885RAB9A 159/4885 |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | MALT1, NR3C2, MRPL21 | NPC1 110/4885MAPT 4658/4885RAB9A 322/4885 |
| US-20070082875-A1 | toll-like receptor-4 agonists; vaccines | TLR4, TLR3, TLR1 | NPC1 2970/4885MAPT 3238/4885RAB9A 1494/4885 |
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | TEAD1, TEAD2, TEAD3 | NPC1 551/4885MAPT 2193/4885RAB9A 1559/4885 |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | NPC1 223/4885MAPT 2253/4885RAB9A 3614/4885 |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL17, RPN2 | NPC1 143/4885MAPT 4356/4885RAB9A 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.